Yes, I was aware that CYDY had contacted the FDA a

Yes, I was aware that CYDY had contacted the FDA and intravenous dosing option was declined.

And this is exactly the pivot point at which I believe a different outcome should have been achieved.

Of course if CD12 mortality reduction is greater than 30%, all of my criticisms are proven completely and unequivocally wrong.

In the case of CD12 mortality greater less than 30%, any and all criticism will be completely and totally silenced.

One problem I have (no doubt amongst many others) is that I have difficulty imagining how an intravenous conversation with the FDA would proceed.

CYDY: "How about we dose some intravenous?"

FDA: "No."

CYDY: "But with very fast CCR5 blockade, the emergent patients might be saved."

FDA: "RO has no relevance to covid. We don't believe in your CCR5 theory for even one minute. We only green lighted you for CD10 and CD12 cuz we are desperate to try anything."

Or maybe:

FDA: "What is RO and why would it be related to IV dosing of LL in covid?"

Or maybe:

FDA: "Sure, go right ahead with a phase 3 for intravenous dosing. another 390 patients would do just fine."

Covid patients are emergent. Stands to reason that IV will work better in emergent covid patients.

Everyone has a difficult job. Sometimes you just need some help with your work.